<DOC>
	<DOCNO>NCT00886756</DOCNO>
	<brief_summary>This Phase I , double-blind , placebo-controlled , randomise within dose group , single ascend dose study , objective ass safety , tolerability pharmacokinetic profile AZD8529 healthy Japanese subject .</brief_summary>
	<brief_title>AZD8529 Single Ascending Dose Study Healthy Japanese Subjects</brief_title>
	<detailed_description />
	<criteria>Healthy male Japanese subject age 20 45 year ( inclusive ) Have body mass index ( BMI ) 18 27 kg/m 2 ( inclusive ) weigh least 50 kg.least 50 kg . History clinically significant disease disorder , opinion Investigator , may either put subject risk participation study , influence result subject 's ability participate study . Any clinically relevant abnormality physical examination , vital sign , clinical chemistry , haematology urinalysis judge Investigator and/or Sponsor . Smoking excess 5 cigarette per day equivalent within 28 day Day 1 .</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>Phase I</keyword>
	<keyword>Japanese healthy volunteer</keyword>
	<keyword>AZD8529</keyword>
</DOC>